Mesoblast Limited

As of June 30, 2026, Mesoblast Limited carries a market capitalization of 2.53B, placing it among publicly traded companies globally. Its enterprise value stands at 2.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mesoblast Limited's next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2026, Mesoblast Limited has 1.30B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Mesoblast Limited maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Mesoblast Limited's stock has declined approximately 32.22% over the past 52 weeks. The 50-day moving average sits at 2.16, while the 200-day moving average is 2.20.

As of June 30, 2026, Mesoblast Limited holds 68.48M in cash and equivalents against 184.00M in total debt, resulting in a net debt position of 103.82M. Total book value stands at 821.35M, with working capital of 168.17M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Mesoblast Limited paid dividends of - - per share. Total shareholder yield reaches 0.88, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Mesoblast Limited shareholders.

Mesoblast Limited's most recent stock split took place on December 5, 2023 with a 128:135 split ratio.